Supernus Pharmaceuticals (SUPN) – Analysts’ Recent Ratings Updates

by · The Cerbat Gem

A number of research firms have changed their ratings and price targets for Supernus Pharmaceuticals (NASDAQ: SUPN):

  • 11/25/2025 – Supernus Pharmaceuticals had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
  • 11/19/2025 – Supernus Pharmaceuticals had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
  • 11/13/2025 – Supernus Pharmaceuticals was downgraded by analysts at Weiss Ratings from a “hold (c+)” rating to a “sell (d+)” rating.
  • 11/8/2025 – Supernus Pharmaceuticals was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
  • 10/29/2025 – Supernus Pharmaceuticals is now covered by analysts at Bank of America Corporation. They set a “buy” rating and a $65.00 price target on the stock.
  • 10/23/2025 – Supernus Pharmaceuticals had its price target raised by analysts at TD Cowen from $45.00 to $60.00. They now have a “buy” rating on the stock.
  • 10/9/2025 – Supernus Pharmaceuticals was upgraded by analysts at Piper Sandler from a “neutral” rating to an “overweight” rating. They now have a $65.00 price target on the stock, up previously from $40.00.
  • 10/8/2025 – Supernus Pharmaceuticals had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
  • 10/3/2025 – Supernus Pharmaceuticals was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
  • 9/30/2025 – Supernus Pharmaceuticals had its price target raised by analysts at Cantor Fitzgerald from $46.00 to $63.00. They now have an “overweight” rating on the stock.

Insider Transactions at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, SVP Frank Mottola sold 5,000 shares of Supernus Pharmaceuticals stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $45.87, for a total value of $229,350.00. Following the completion of the transaction, the senior vice president directly owned 15,496 shares of the company’s stock, valued at approximately $710,801.52. The trade was a 24.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Jack A. Khattar sold 59,900 shares of the business’s stock in a transaction dated Thursday, October 9th. The stock was sold at an average price of $50.57, for a total value of $3,029,143.00. Following the completion of the transaction, the chief executive officer directly owned 1,206,578 shares of the company’s stock, valued at approximately $61,016,649.46. This trade represents a 4.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 183,135 shares of company stock valued at $8,773,587. 8.80% of the stock is owned by company insiders.

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.

Featured Articles